AI Article Synopsis
- Vitamin D plays a role in Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), particularly affecting secondary hyperparathyroidism in hemodialysis (HD) patients, and while cholecalciferol is recommended for vitamin D deficiency, its effects on CKD-MBD are not entirely clear.
- An observational study involved 22 HD patients with vitamin D levels between 30-50 ng/mL receiving cholecalciferol to boost their levels above 75 ng/mL, comparing baseline biochemical markers with those at higher vitamin D levels.
- The study found that 73% of participants achieved the target vitamin D level in about 7.5 weeks with a total dose of 525,000
Article Abstract
(1) : Vitamin D is implicated in the pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) in hemodialysis (HD) patients, including the development of secondary hyperparathyroidism (SHP). While cholecalciferol supplementation is recommended for vitamin D deficiency correction, its impact on CKD-MBD remains inconsistent. The aim of this observational prospective study was to assess the effect of cholecalciferol in achieving high-normal serum 25-hydroxycholecalciferol (25(OH)D > 75 ng/mL) levels and its impact on CKD-MBD biochemical markers, including 1,25-dihydroxycholecalciferol (1,25(OH)D) and parathormone (PTH) in HD patients. The study also evaluated the maintenance dosage required to sustain 25(OH)D levels within the 50-75 ng/mL range. (2) : A total of 22 HD patients with baseline 25(OH)D levels 30-50 ng/mL received cholecalciferol (70,000 IU/week) to achieve the target serum 25(OH)D > 75 ng/mL. Baseline data on calcium, phosphate, 1-84 PTH, 25(OH)D, and 1,25(OH)D serum levels were compared with the data when 25(OH)D > 75 ng/mL was targeted or when the highest 25(OH)D levels were noted. (3) : Cholecalciferol significantly improved vitamin D status in HD patients, with 73% reaching the target 25(OH)D level >75 ng/mL in a median time of 7.5 weeks, with a median total dose of 525,000 IU. This was associated with a significant rise in 1,25(OH)D, decrease in 1-84 PTH, and no significant effect on calcium and phosphate levels. The median maintenance dose of cholecalciferol was established at 30,000 IU/week. (4) : The findings support the use of cholecalciferol targeting high normal 25(OH)D levels to improve biochemical markers of CKD-MBD in HD patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11596388 | PMC |
| http://dx.doi.org/10.3390/medicina60111831 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Simple prediction model for vitamin D deficiency in women with osteoporosis or risk factors for osteoporosis in Thailand.
J Clin Transl Endocrinol
December 2024
Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama 6 Road, Ratchathewi, Bangkok 10400, Thailand.
Introduction: In Thailand, the assessment of vitamin D status by measuring 25-hydroxyvitamin D[25(OH)D] levels in individuals at risk for osteoporosis is constrained by limited facilities and high costs. This study aimed to create a clinical model for predicting vitamin D deficiency in women with osteoporosis or risk factors for osteoporosis.
Materials And Methods: This was a cross-sectional study of 490 women.
Association of Vitamin D Status with Immune Markers in a Cohort of Healthy Adults.
J Nutr
December 2024
Department of Nutrition, University of California, Davis, Davis, CA, United States; USDA Western Human Nutrition Research Center, University of California, Davis, Davis, CA, United States. Electronic address:
Background: Immune function is affected by vitamin D status but the optimal serum 25-hydroxy vitamin D [25(OH)D] level for immune function is not known.
Objectives: We hypothesized that 25(OH)D would be associated with markers of inflammation and immune activation.
Methods: We identified associations between 25(OH)D and immune markers from 361 healthy adults using polynomial regression.
Correlation and mediation analysis between plasmapheresis donation behavior and bone mineral density and bone metabolism biomarkers: a cross-sectional study based on plasmapheresis donors at high risk of osteoporosis in China.
PeerJ
December 2024
Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, Chengdu, China.
Background: As a group of more than 3.67 million people, the bone health of Chinese plasmapheresis donors, which the main population is also a risk group of osteoporosis (OP), has raised concerns. Therefore, this article investigates the relationship between bone mineral density (BMD), bone metabolism indicators, and plasmapheresis donation behavior among some high-risk plasmapheresis donors for OP in China, and further explores the mediating factors through reasonable statistical methods.
View Article and Find Full Text PDFGlucose regulation and association with Vitamin D and parathyroid hormone - differences across Middle Eastern and Caucasian ethnicities.
J Diabetes Metab Disord
June 2025
Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.
Background: Middle Eastern (ME) immigrants to Europe have a heavy burden of metabolic disorders including a higher prevalence of insulin resistance, T2D and obesity as compared to native-born Europeans. Vitamin D insufficiency and deficiency are prevalent conditions in people originating from the ME.
Aims: To study the differences in the levels of 25(OH)D and parathyroid hormone (PTH) across ME and European ethnicity, and the effect of 25(OH)D and PTH on insulin action and secretion.
Differential seasonal performance of C3-epi-D3 level and proportion on multiple metabolic disorders in patients with type 2 diabetes mellitus.
Eur J Med Res
December 2024
Mianyang Central Hospital, Affiliated to School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Background And Aim: Recent Mendelian randomization and meta analysis suggest a controversial causality between C3-epimer of 25 hydroxyvitamin D3 (C3-epi-D3) and type 2 diabetes mellitus (T2DM). The clinical evidence regarding the impact of C3-epi-D3 on the progression of T2DM is currently insufficient. This study aims to investigate whether C3-epi-D3 has any effect on metabolic disorders of T2DM patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!